• No one should be alone in this. We can help.
If you - or someone you know - are having thoughts about suicide, call 1-800-273-TALK (8255). Calls are connected to a certified crisis center nearest the caller's location. Services are available 24 hours a day, seven days a week.                                                                            If you - or someone you know - are having thoughts about suicide, call 1-800-273-TALK (8255). Calls are connected to a certified crisis center nearest the caller's location. Services are available 24 hours a day, seven days a week.
Advertisement

Main Menu
Sponsored Links
Donate to DF
Latest Forum Topics
No posts were found
Search

Find a Therapist
Powered by Good Therapy
Lindsay  Lindsay

Evidence-Based Treatment of Pediatric Bipolar Disorder

Evidence-Based Treatment of Pediatric Bipolar Disorder



 
Robert L. Findling, MD


In the past few years, we’ve seen a growing body of scientific evidence that supports the efficacy of mood stabilizers and atypical antipsychotics to treat young patients with bipolar disorder. Lithium, olanzapine, aripiprazole, and risperidone monotherapy are FDA-approved for manic or mixed states in pediatric patients, while quetiapine is approved as monotherapy or as an adjunct to lithium or divalproex for manic states.
We’ve also learned more about the safety and tolerability of approved medications in this population. Lithium is generally well tolerated in children and adolescents, but does have the potential to cause thyroid and renal dysfunction and can be toxic in overdose1; blood monitoring is therefore essential when using lithium. Atypical antipsychotics can also have adverse effects, and children and adolescents appear to be at a higher risk for these than adults.2 Somnolence is one of the most common side effects; others include sedation, weight gain, negative metabolic effects, prolactin elevation, and EPS. However, side effect profiles do differ within the class: olanzapine has the greatest association with weight gain and adverse metabolic effects, while aripiprazole has the least. When prescribing an atypical, obtain baseline metabolic measures and regularly monitor your young patients.
Other medications have been studied for pediatric bipolar disorder, but, so far, the results are mixed. For instance, divalproex may3 or may not4 be more effective than placebo for treating mania. The anticonvulsant oxcarbazepine5 didn’t show a significant benefit for mania or mixed symptoms compared with placebo, and topiramate6 had inconclusive evidence. An open-label study7 found lamotrigine to be effective as monotherapy or as adjunctive treatment in pediatric bipolar depression, and preliminary findings suggest clozapine may benefit pediatric patients with treatment-resistant manic or mixed episodes.8
Obviously, more comparative and placebo-controlled studies are needed for these and other medications. New research on the safety and efficacy of combination therapies to treat children and adolescents with bipolar disorder could really help clinicians, young patients, and their families make evidence-based decisions. But, effective and generally well-tolerated medications are available to treat these young patients that can, when combined with psychosocial approaches that focus on academic, social, and family functioning, relieve some of the burden associated with this complex and potentially devastating illness.
Financial Disclosure: Dr Findling, in the past 12 months, has received research support from AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Merck, Otsuka, Pfizer, Rhodes, Shire, Supernus, and Wyeth; has served as a consultant to Alexza, Bristol-Myers Squibb, Forest, GlaxoSmithKline, KemPharm, Eli Lilly, Lundbeck, Merck, Novartis, Noven, Otsuka, Pfizer, Schering-Plough, Seaside Therapeutics, Sepracor, Shire, Sunovion, Supernus, and Transcept; and has served as a speaker for Shire.
Abbreviations: EPS = extrapyramidal symptoms, FDA = US Food and Drug Administration
REFERENCES
1. Smarty S, Findling RL. Psychopharmacology of pediatric bipolar disorder: a review. Psychopharmacology (Berl). 2007;191(1):39–54.
2. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008;69(suppl 4):26–36.
3. Kowatch RA, Findling RL, Scheffer RE, et al. Pediatric bipolar collaborative mood stabilizer trial. Poster presented at: 54th annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP); October 23–28, 2007; Boston, MA.
4. Wagner KD, Redden L, Kowatch RA, et al. A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009;48(5):519–532.
5. Wagner KD, Kowatch RA, Emslie GJ, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents [published correction appears in Am J Psychiatry. 2006;163(10):1843]. Am J Psychiatry. 2006;163(7):1179–1186.
6. DelBello MP, Findling RL, Kushner S, et al. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(6):539–547.
7. Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry. 2006;45(3):298–304.
8. Masi G, Mucci M, Millepiedi S. Clozapine in adolescent inpatients with acute mania. J Child Adolesc Psychopharmacol. 2002;12(2):93–99.

University Hospitals Case Medical Center,
Case Western Reserve University, Cleveland, Ohio

This Month In Pictures
pinecones.jpg
Members Online
0 Users Online
Guests
Visible
No users online.
Follow Us On Twitter
Like Us On Facebook
Medical News
  • Dementia: Bilingualism may help brain conserve resources and resist decline
    New research suggests years of bilingualism alters the brain to use resources more efficiently when concentrating, giving insights to successful aging.
    Psychology / Psychiatry News From Medical News Today
    Monday, 16 January 2017 09:00
  • Benzodiazepines and related drugs increase stroke risk among persons with Alzheimer's disease
    The use of benzodiazepines and benzodiazepine-like drugs was associated with a 20 per cent increased risk of stroke among persons with Alzheimer's disease, shows a recent study from the University...
    Psychology / Psychiatry News From Medical News Today
    Monday, 16 January 2017 08:00
  • Is Neurofeedback an Effective Treatment for ADHD?
    What is neurofeedback and does it work when treating ADHD? What should be considered when using neurofeedback and what should be expected from treatment?
    ADHD News From Medical News Today
    Monday, 16 January 2017 08:00
  • Schizophrenia could directly increase risk of diabetes
    People with early schizophrenia are at an increased risk of developing diabetes, even when the effects of antipsychotic drugs, diet and exercise are taken out of the equation, according to an...
    Psychology / Psychiatry News From Medical News Today
    Monday, 16 January 2017 02:00
  • Annual report examines state of college student mental heath
    Despite increased demand for counseling centers on college campuses, students aren't necessarily getting sicker.
    Mental Health News From Medical News Today
    Monday, 16 January 2017 02:00
  • Natural Remedies for ADHD
    Learn about natural remedies for treating the symptoms of ADHD. This article looks how supplements and lifestyle changes may be able to help.
    ADHD News From Medical News Today
    Monday, 16 January 2017 02:00
  • Can chair yoga relieve osteoarthritis pain?
    A new randomized control study is the first to show that chair yoga can help to reduce pain in seniors with lower extremity osteoarthritis.
    Pain / Anesthetics News From Medical News Today
    Sunday, 15 January 2017 02:00
  • Musicians have faster reaction times
    New research demonstrates that musical training improves reaction time to auditory and tactile stimuli. The findings open the door to new types of therapy.
    Psychology / Psychiatry News From Medical News Today
    Saturday, 14 January 2017 02:00
  • What are the risks and benefits of cannabis use? New report sheds light
    The National Academies of Sciences, Engineering, and Medicine have analyzed over 10,000 studies to better understand the benefits and harms of cannabis.
    Mental Health News From Medical News Today
    Friday, 13 January 2017 11:00
  • Can Marijuana Help Treat ADHD?
    Learn if marijuana affects ADHD and if medical marijuana is available as a treatment. What are the risks, and can marijuana treat children with ADHD?
    ADHD News From Medical News Today
    Friday, 13 January 2017 08:00
  • Scientists find new mechanism for memory formation
    New research investigates how we form memories, and discovers that apart from the hippocampus, a previously neglected brain area plays a crucial role.
    Psychology / Psychiatry News From Medical News Today
    Friday, 13 January 2017 02:00
  • Bacterial protein structure could aid development of new antibiotics
    Bacterial cells have an added layer of protection, called the cell wall, that animal cells don't.
    Pharma Industry / Biotech Industry News From Medical News Today
    Friday, 13 January 2017 02:00
Suicide Prevention Lifeline
suicidepreventionlifeline.org
Andertoon
Daily Toon Click to enlarge
ANDERTOONS.COM PSYCHIATRY CARTOONSPsychiatry Cartoonsby Andertoons
Tweets Liked by ~ Lindsay (@DepressionForum)
Depression Forums - A Depression & Mental Health Community Support Group
Copyright © 2014 The Depression Forums Incorporated - A Depression & Mental Health Social Community Support Group. All rights reserved.
The Depression Forums are intended to enable members to benefit from the experience of other members who have faced similar mental health issues by sharing their experiences.
* DF does NOT vouch for or warrant the accuracy, completeness or usefulness of any posting or the qualifications of any person responding.
Use of the Forums is subject to our Terms Of Service (TOS) and forum guidelines which prohibit advertisements, solicitations or other commercial messages by members, or false, defamatory, abusive, vulgar, or harassing messages and may subject violators to be banned from the forums.
All postings reflect the views of the author but become the property of DepressionForums.org. Your personal information will never be shared with others.
If you have any questions on how it will be used, please see our our privacy policy.
Information supplied on Depression Forums should not be relied upon and is not a substitute for medical advice from a health professional or doctor.
* DF © is an acronym for DepressionForums.org